Scilex Holding Company's Schedule 13D Filing for Semnur Pharmaceuticals, Inc.

Scilex Holding Company (SHC) and its subsidiary Scilex, Inc. filed a Schedule 13D with the SEC regarding their ownership of Semnur Pharmaceuticals, Inc. The filing details the business combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, which was completed on September 22, 2025. SHC and Scilex, Inc. hold significant shares of Semnur's common stock, with SHC directly holding 1,054,849 shares and Scilex, Inc. holding 181,804,849 shares. Additionally, SHC holds 5,423,606 shares of Semnur's Series A Preferred Stock. The filing also outlines various agreements, including a Debt Exchange Agreement, a Convertible Promissory Note, and a Sponsor Interest Purchase Agreement. Post-business combination, SHC and Scilex, Inc. transferred 12,500,000 shares of Semnur's common stock to a third party. The filing provides detailed information on the transactions and agreements that led to the current ownership structure.